Enliven Therapeutics, Inc. Quarterly Depreciation in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Enliven Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q1 2020 to Q1 2024.
  • Enliven Therapeutics, Inc. Depreciation for the quarter ending March 31, 2024 was $79K, a 17.9% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Depreciation for 2023 was $297K, a 38.1% increase from 2022.
  • Enliven Therapeutics, Inc. annual Depreciation for 2022 was $215K, a 87% increase from 2021.
  • Enliven Therapeutics, Inc. annual Depreciation for 2021 was $115K, a 18.6% increase from 2020.
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $79K +$12K +17.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q1 2023 $67K +$28K +71.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2022 $39K +$14K +56% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $25K +$1K +4.17% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 $24K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.